Provention Bio to Present at the Jefferies Global Healthcare Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Provention Bio, Inc. (Nasdaq: PRVB) announced its participation in the Jefferies Global Healthcare Conference on June 8, 2022, at 9:00 am EST in New York City. The corporate presentation will be available via live webcast through the company's website, where it will be archived for 30 days post-event. Provention Bio focuses on developing therapies for immune-mediated diseases, with ongoing research in conditions like type 1 diabetes and lupus.
Details
News Market Reaction – PRVB
The recorded move for PRVB in the trading session of this news was +5.45%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
RED BANK, N.J., June 3, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that management will participate in a corporate presentation at the Jefferies Global Healthcare Conference on Wednesday, June 8th 2022 at 9:00 am EST in New York City.
The presentation will be webcast live and can be accessed by visiting the Events and Webcasts section of the Company's website: http://investors.proventionbio.com/events. The webcast will be archived on the Company's website for 30 days following the presentation.
Provention Bio, Inc. (Nasdaq: PRVB) is a biopharmaceutical company focused on advancing the development of investigational therapies that may intercept and prevent debilitating and life-threatening immune-mediated disease. The Company's pipeline includes clinical-stage product candidates that have demonstrated in pre-clinical or clinical studies proof-of-mechanism and/or proof-of-concept in autoimmune diseases, including type 1 diabetes, celiac disease and lupus. Visit www.ProventionBio.com for more information and follow us on Twitter: @ProventionBio.
Provention Bio, Inc. uses its website, www.proventionbio.com, as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation F.D. Such disclosures will be included on the Company's website in the "News" section. Accordingly, investors should monitor this portion of the Company's website, in addition to following its press releases, SEC filings and public conference calls and webcasts.
Investor Contact:
Robert Doody, VP of Investor Relations
rdoody@proventionbio.com
484-639-7235
Media Contact:
Kaelan Hollon, VP, Corporate Communications
khollon@proventionbio.com
202-421-4921
View original content to download multimedia:https://www.prnewswire.com/news-releases/provention-bio-to-present-at-the-jefferies-global-healthcare-conference-301560699.html
SOURCE Provention Bio, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.